:format(webp)/cdn.mskdoctors.com/storage/2026/6/Ve9V5o28ujztizkD5TuIOycurhx13Uwl.jpg)
When cartilage repair is the right choiceCartilage repair succeeds for a focal defect in otherwise healthy joint tissue in younger patients, but fails in diffuse arthritis. Lesion size, depth, patient age, and activity level determine the appropriate technique.Cartilage repair succeeds for a focal defect in otherwise healthy joint tissue in younger patients, but fails in diffuse arthritis. Lesion size, depth, patient age, and activity level determine the appropriate technique.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/fXuiSujBVtA48fh43VpqUIrNtGZ4Frrw.jpg)
ChondroFiller injection cost and what affects itChondroFiller injection costs £3,000–£8,000 depending on cartilage defect size: one box £3,000, two boxes £5,500, three boxes £8,000, each including consultation, ultrasound guidance, implant, injection and six-week follow-up.ChondroFiller injection costs £3,000–£8,000 depending on cartilage defect size: one box £3,000, two boxes £5,500, three boxes £8,000, each including consultation, ultrasound guidance, implant, injection and six-week follow-up.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/hxv2WSJ4H38qGrp7BY6BuYMYkHxE94An.jpg)
How ACI and MACI differ for cartilage repairMACI pre-seeds cultured chondrocytes onto a collagen membrane fixed with fibrin glue, eliminating the sutures required in earlier ACI variants. The technique enables arthroscopic implantation and supports faster recovery than open surgical approaches.MACI pre-seeds cultured chondrocytes onto a collagen membrane fixed with fibrin glue, eliminating the sutures required in earlier ACI variants. The technique enables arthroscopic implantation and supports faster recovery than open surgical approaches.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/Ftb0eLP1qk86rzkUGQIcwelqCKAR75gI.jpg)
ChondroFiller injection vs PRP for cartilage repairChondroFiller fills focal cartilage defects with a collagen scaffold; PRP modulates inflammation in diffuse wear. MRI findings, not symptoms, determine which applies.ChondroFiller fills focal cartilage defects with a collagen scaffold; PRP modulates inflammation in diffuse wear. MRI findings, not symptoms, determine which applies.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/D0tyzIsoQnbBzYhAvckIJheDPxvE9YFg.jpg)
Injectable scaffold vs surgical knee cartilage repairFor focal knee cartilage defects, injectable collagen scaffolds provide a non-surgical treatment by acting as an acellular matrix that guides the patient's own progenitor cells in regenerating cartilage-like tissue, overcoming cartilage's inability to repair itself due to lacking blood supply.For focal knee cartilage defects, injectable collagen scaffolds provide a non-surgical treatment by acting as an acellular matrix that guides the patient's own progenitor cells in regenerating cartilage-like tissue, overcoming cartilage's inability to repair itself due to lacking blood supply.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/Pnxd3GmAoqDdpILnLTGgWOfeUfbRItl0.jpg)
AMIC versus MACI for focal cartilage repairAMIC repairs focal cartilage defects in one operation: drilling channels into damaged cartilage releases a blood clot rich in stem cells, which a collagen membrane then stabilises and concentrates to guide tissue repair. A 2025 trial found it equivalent to MACI at two years.AMIC repairs focal cartilage defects in one operation: drilling channels into damaged cartilage releases a blood clot rich in stem cells, which a collagen membrane then stabilises and concentrates to guide tissue repair. A 2025 trial found it equivalent to MACI at two years.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/57s18HJqAXR5l5fNKN3AOCVygSdgfLOY.jpg)
ChondroFiller durability vs Arthrosamid and hyaluronic acidChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.ChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/Lj6L1IaL5TBE3CuCl6wA8ci1T5bHoA72.jpg)
ChondroFiller success rates in practiceChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.ChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.
:format(webp)/cdn.mskdoctors.com/storage/2026/5/5jXngqcNh5j74Qe4t1F62D4w54YwW6Sb.jpg)
Choosing joint preserving surgery before knee replacementOne-compartment knee wear does not automatically mean replacement is next: bracing, osteotomy and focal cartilage repair can reduce pain and delay arthroplasty when alignment and damage remain localised. Microfracture is now usually limited to very small defects, while AMIC, MACI, OATS and OCA are chosen by lesion size, depth and…One-compartment knee wear does not automatically mean replacement is next: bracing, osteotomy and focal cartilage repair can reduce pain and delay arthroplasty when alignment and damage remain localised. Microfracture is now usually limited to very small defects, while AMIC, MACI, OATS and OCA are chosen by lesion size, depth and joint health.
:format(webp)/cdn.mskdoctors.com/storage/2026/5/Y4KYtf5PTSB1sM89QjcVcpPuhlKwX9JB.jpg)
ChondroFiller and cortisone treat different knee problemsCortisone and ChondroFiller treat different knee problems: cortisone is short-term symptom control for diffuse osteoarthritis or an inflammatory flare, with benefit usually measured in weeks to a few months, while ChondroFiller is a single-stage cell-free collagen scaffold designed for clearly localised grade III or IV cartilage defects and selected osteochondral…Cortisone and ChondroFiller treat different knee problems: cortisone is short-term symptom control for diffuse osteoarthritis or an inflammatory flare, with benefit usually measured in weeks to a few months, while ChondroFiller is a single-stage cell-free collagen scaffold designed for clearly localised grade III or IV cartilage defects and selected osteochondral lesions. A broadly worn knee should not assume a focal scaffold will help, and a defined cartilage lesion should not assume a cortison...
:format(webp)/cdn.mskdoctors.com/storage/2026/5/PkceL2jRm6AEpsGwqStgtOY5GBKWnFaq.jpg)
BMAC or exosomes for knee osteoarthritisBMAC currently has the firmer clinical footing for knee osteoarthritis: a meta-analysis of 27 Level I studies showed BMAC and PRP both outperformed hyaluronic acid, but BMAC was not significantly better than PRP, and improvement is largely about pain and function rather than proven cartilage repair. Kellgren-Lawrence grade 2 knees…BMAC currently has the firmer clinical footing for knee osteoarthritis: a meta-analysis of 27 Level I studies showed BMAC and PRP both outperformed hyaluronic acid, but BMAC was not significantly better than PRP, and improvement is largely about pain and function rather than proven cartilage repair. Kellgren-Lawrence grade 2 knees respond better than more advanced disease, but harvest sites, processing and injection protocols still vary widely between studies. Exosomes have no FDA-approved produ...
:format(webp)/cdn.mskdoctors.com/storage/2026/5/abV3BrK73uU8EhUXEgihyuUTER4ZQ1Ug.jpg)
BMAC or exosomes for knee osteoarthritisThe article compares the evidence for BMAC and exosome injections in knee osteoarthritis, explaining that BMAC has stronger support for short-term pain and function improvement, especially in earlier disease, while exosomes remain experimental and unapproved. It also sets out what to ask clinics about preparation, suitability, safety and follow-up.The article compares the evidence for BMAC and exosome injections in knee osteoarthritis, explaining that BMAC has stronger support for short-term pain and function improvement, especially in earlier disease, while exosomes remain experimental and unapproved. It also sets out what to ask clinics about preparation, suitability, safety and follow-up.
